Retatrutide dosage protocol
Retatrutide dosing follows a slow-escalation protocol designed to minimize gastrointestinal side effects while reaching the therapeutically effective dose range. The Phase 2 clinical trial tested multiple dose levels from 1 mg to 12 mg weekly, providing clear dose-response data that informs both clinical and research dosing approaches.
Retatrutide dosage: Phase 2 dose levels and weight loss
| Dose group | Weekly dose | Weight loss at 48 weeks | Escalation schedule |
|---|---|---|---|
| Group 1 | 1 mg | ~8.7% | No escalation (fixed dose) |
| Group 2 | 4 mg | ~17.1% | 2 mg × 4 wk → 4 mg |
| Group 3 | 4 mg (rapid) | ~17.1% | 4 mg from start (no escalation) |
| Group 4 | 8 mg | ~22.8% | 2 mg × 4 wk → 4 mg × 4 wk → 8 mg |
| Group 5 | 8 mg (rapid) | ~22.8% | 4 mg × 4 wk → 8 mg |
| Group 6 | 12 mg | ~24.2% | 2 mg × 4 wk → 4 mg × 4 wk → 8 mg × 4 wk → 12 mg |
| Placebo | — | ~2.1% | — |
The dose-response relationship is clear: higher retatrutide doses produce greater weight loss. The 12 mg dose achieved the maximum 24.2% mean weight loss, but the 8 mg dose achieved 22.8% — only 1.4 percentage points less. This suggests that the 8–12 mg range represents the plateau of the dose-response curve, where additional dose increases produce diminishing marginal returns in weight loss while increasing side effect burden.
Retatrutide dosage: titration schedule
The Phase 2 trial used a slow escalation approach for the 12 mg group — starting at 2 mg and increasing by one dose level every 4 weeks (2 → 4 → 8 → 12 mg). This 12-week escalation period is critical for tolerability. Groups that used faster escalation (e.g., starting at 4 mg without a 2 mg lead-in) experienced higher rates of GI side effects. The slow titration allows the GI tract to adapt to GLP-1 receptor activation before the full triple-agonist signal is applied at higher doses.
Retatrutide dosage escalation (12 mg target)
Weeks 1–4: 2 mg/week. Weeks 5–8: 4 mg/week. Weeks 9–12: 8 mg/week. Week 13+: 12 mg/week (maintenance). All doses administered as once-weekly subcutaneous injection. This schedule mirrors the clinical trial protocol and minimizes GI side effects during escalation.
Retatrutide dosage: administration
Retatrutide is administered as a once-weekly subcutaneous injection. In clinical trials, the injection was delivered via a pre-filled syringe or auto-injector pen into the abdomen, thigh, or upper arm. The injection site should be rotated weekly. The once-weekly schedule is made possible by molecular modifications (fatty acid acylation) that extend the peptide's half-life in circulation — the same engineering approach used in semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound).
Retatrutide can be administered on any day of the week, with or without food. Consistency in timing (same day each week) is recommended for steady-state blood levels but is not pharmacologically required. If a dose is missed, it should be taken as soon as remembered unless the next scheduled dose is within 3 days, in which case the missed dose should be skipped.
Retatrutide dosage: research-grade considerations
Research-grade retatrutide available through peptide suppliers is typically supplied as lyophilized powder in vials (5 mg or 10 mg), requiring reconstitution with bacteriostatic water before injection. This is a different format from the pharmaceutical pre-filled pens used in clinical trials. Users of research-grade retatrutide must calculate injection volumes based on reconstitution concentration — a process that introduces dosing variability and potential errors compared to the standardized pharmaceutical format.
It is critical to note that research-grade retatrutide has not been reviewed by the FDA for purity, potency, or sterility. Actual peptide content may differ from the labeled amount, and contaminants may be present. The clinical trial results described on this site were achieved with pharmaceutical-grade retatrutide manufactured under GMP conditions by Eli Lilly — research-grade products may not replicate these results. See the retatrutide cost and availability page for current pricing and sourcing information.
What is the best retatrutide dosage for weight loss?
In the Phase 2 trial, the 12 mg weekly dose produced the greatest weight loss (24.2%). However, the 8 mg dose achieved 22.8% — nearly as effective with potentially fewer side effects. The optimal dose balances efficacy against tolerability. Phase 3 trials will help determine whether the 8 mg or 12 mg dose (or both) will be submitted for FDA approval.
How often do you inject retatrutide?
Once weekly. This is the same injection frequency as semaglutide (Wegovy) and tirzepatide (Mounjaro/Zepbound). The long half-life achieved through fatty acid acylation allows therapeutic levels to be maintained with weekly dosing.
Can you take retatrutide daily instead of weekly?
No — retatrutide was designed and tested as a once-weekly injection. The molecular modifications that extend its half-life produce sustained receptor activation over 7 days. Daily dosing would create supraphysiological receptor stimulation and significantly worsen side effects without proportional additional benefit. The clinical trial data applies only to the once-weekly dosing schedule.